Active Ingredient History
Pemetrexed is a new-generation antifolate, approved for the treatment of mesothelioma and non-small cell lung cancer, currently being evaluated for the treatment of a variety of other solid tumors. Pemetrexed, is a folate analog metabolic inhibitor that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) and and to a lesser extent aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life resulting in prolonged drug action in malignant cells. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Mesothelioma (approved 2004)
Adenocarcinoma (Phase 4)
Adenocarcinoma, Bronchiolo-Alveolar (Phase 2)
Adenocarcinoma of Lung (Phase 4)
Angiogenesis Modulating Agents (Phase 2)
Antineoplastic Agents (Phase 1/Phase 2)
Bevacizumab (Phase 2)
Bile Duct Neoplasms (Phase 1/Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 2)
Bronchial Diseases (Phase 3)
Bronchial Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Bronchogenic (Phase 3)
Carcinoma, Ductal (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Small Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 3)
Central Nervous System Neoplasms (Phase 2)
Cervical Intraepithelial Neoplasia (Phase 2)
Chemotherapy, Adjuvant (Phase 2)
Chordoma (Phase 1)
Choriocarcinoma (Phase 2)
Circulating Tumor DNA (Phase 2)
Colorectal Neoplasms (Phase 2)
Cytoreduction Surgical Procedures (Phase 2)
Docetaxel (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Drug Therapy, Combination (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 2)
Epidermal Growth Factor (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 1/Phase 2)
Gastrointestinal Neoplasms (Phase 2)
General Surgery (Phase 2)
Genital Neoplasms, Female (Phase 2)
Gestational Trophoblastic Disease (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 3)
Hydatidiform Mole (Phase 2)
Immunotherapy (Phase 2)
Lapatinib (Phase 1/Phase 2)
Leukemia (Early Phase 1)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoproliferative Disorders (Early Phase 1)
Medical Oncology (Phase 1)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 4)
Mesothelioma, Malignant (Phase 3)
Multiple Myeloma (Early Phase 1)
Mutation (Phase 3)
Myelodysplastic Syndromes (Early Phase 1)
Myeloproliferative Disorders (Early Phase 1)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 4)
Neoplasms by Histologic Type (Phase 3)
Neoplasms by Site (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 3)
Neoplasms, Nerve Tissue (Phase 3)
Neuregulin-1 (Phase 2)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Oncogene Proteins (Phase 2)
Oncogenes (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 3)
Pemetrexed (Phase 2)
Peritoneal Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Pleura (Phase 2)
Pleural Neoplasms (Phase 2)
Precancerous Conditions (Early Phase 1)
Primary Myelofibrosis (Early Phase 1)
Prostatic Neoplasms (Phase 2)
Protein Kinase Inhibitors (Phase 1/Phase 2)
Radiation Oncology (Phase 2)
Radiosurgery (Phase 2)
Radiotherapy (Phase 3)
Rectal Neoplasms (Phase 2)
Respiratory Tract Diseases (Phase 3)
Respiratory Tract Neoplasms (Phase 3)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Therapeutics (Phase 2)
Thoracic Neoplasms (Phase 3)
Thymidylate Synthase (Phase 2)
Thymoma (Phase 2)
Thymus Neoplasms (Phase 1)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 1)
Trophoblastic Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urogenital Neoplasms (Phase 2)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
